CA3212731A1 - A pi3k-delta inhibitor for use in treatment regimens - Google Patents

A pi3k-delta inhibitor for use in treatment regimens Download PDF

Info

Publication number
CA3212731A1
CA3212731A1 CA3212731A CA3212731A CA3212731A1 CA 3212731 A1 CA3212731 A1 CA 3212731A1 CA 3212731 A CA3212731 A CA 3212731A CA 3212731 A CA3212731 A CA 3212731A CA 3212731 A1 CA3212731 A1 CA 3212731A1
Authority
CA
Canada
Prior art keywords
compound
salt
cancer
treatment
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3212731A
Other languages
English (en)
French (fr)
Inventor
Catherine PICKERING
Lars Van Der Veen
Michael LAHN
Rebeca ZORRILLA
Zoe Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura SA
Original Assignee
Ionctura SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura SA filed Critical Ionctura SA
Publication of CA3212731A1 publication Critical patent/CA3212731A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
CA3212731A 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens Pending CA3212731A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2104416.9 2021-03-29
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
GB2117511.2 2021-12-03
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (1)

Publication Number Publication Date
CA3212731A1 true CA3212731A1 (en) 2022-10-06

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3212731A Pending CA3212731A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Country Status (17)

Country Link
US (2) US12605389B2 (cg-RX-API-DMAC7.html)
EP (2) EP4313058B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839803B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022251843B2 (cg-RX-API-DMAC7.html)
CA (1) CA3212731A1 (cg-RX-API-DMAC7.html)
DK (1) DK4313058T3 (cg-RX-API-DMAC7.html)
ES (1) ES3031295T3 (cg-RX-API-DMAC7.html)
FI (1) FI4313058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250516T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071610T2 (cg-RX-API-DMAC7.html)
LT (1) LT4313058T (cg-RX-API-DMAC7.html)
MX (1) MX2023011442A (cg-RX-API-DMAC7.html)
PL (1) PL4313058T3 (cg-RX-API-DMAC7.html)
PT (1) PT4313058T (cg-RX-API-DMAC7.html)
RS (1) RS66754B1 (cg-RX-API-DMAC7.html)
SI (1) SI4313058T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022207646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184266A1 (en) * 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005518A (es) 2009-11-13 2012-06-19 Merck Serono Sa Derivados de pirazol amina triciclica.
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Also Published As

Publication number Publication date
US20260224587A1 (en) 2026-08-06
PT4313058T (pt) 2025-06-02
LT4313058T (lt) 2025-05-26
RS66754B1 (sr) 2025-05-30
AU2022251843B2 (en) 2026-04-09
HRP20250516T1 (hr) 2025-06-20
SI4313058T1 (sl) 2025-07-31
DK4313058T3 (da) 2025-05-12
EP4744651A2 (en) 2026-05-20
ES3031295T3 (en) 2025-07-07
US20240058351A1 (en) 2024-02-22
HUE071610T2 (hu) 2025-09-28
PL4313058T3 (pl) 2025-06-23
FI4313058T3 (fi) 2025-04-30
MX2023011442A (es) 2023-10-18
JP2024518685A (ja) 2024-05-02
AU2022251843A1 (en) 2023-10-05
EP4313058B1 (en) 2025-03-05
WO2022207646A1 (en) 2022-10-06
JP7839803B2 (ja) 2026-04-02
EP4313058A1 (en) 2024-02-07
US12605389B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
AU2022251843B2 (en) <i>A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS</i>
US9364476B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US20160287592A1 (en) Ibrutinib combination therapy
EP3695839A1 (en) Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
JP6058009B2 (ja) Pi3k−およびmek−阻害剤の相乗的な組合せ
JP2018532756A (ja) インドールアミン2,3−ジオキシゲナーゼを阻害するための医薬組成物と方法、及びその適応
JP2013500257A (ja) Pi3kインヒビターでの肝障害の処置
JP2022518703A (ja) ホスホジエステラーゼ阻害剤を含有する放出調節錠剤製剤
TW202033191A (zh) 新穎藥物組成物及其用途
EP2922827A2 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
US20170224670A1 (en) Drug Combination to Treat Melanoma
JP2013526579A (ja) 組合せ
US20140140991A1 (en) Methods of treating a disease or disorder associated with bruton's tyrosine kinase
KR101739158B1 (ko) 조합물
CN117042778A (zh) 用于治疗方案的PI3K-δ抑制剂
EP4648766A1 (en) Pi3k inhibitors and methods of making and using the same
EP3125935B1 (en) Combinations of cancer therapeutics
TW201726142A (zh) 用於以阿吡莫德治療癌症的生物標記
TW202133853A (zh) 包含PKC-β抑制劑的組合物及其製備方法
TW201625253A (zh) 包含pgd2拮抗劑之伴隨過敏性疾病之症狀之治療用醫藥
KR20180112066A (ko) 피롤로-융합된 6-원의 헤테로시클릭 화합물을 포함하는 약학적 조성물
AU2012321091B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
CN117083283A (zh) 用于癌症治疗的联合疗法
WO2013039197A1 (ja) IκBキナーゼα活性化阻害剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260227

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260326

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH

Effective date: 20260326

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260326

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260326

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260407

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260407

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260407

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260407

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260408

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH

Effective date: 20260409

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260505